Back to top
more

PDL BioPharma (PDLI)

(Delayed Data from NSDQ)

$2.47 USD

2.47
NA

0.00 (0.00%)

Updated Dec 30, 2020 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PDL BioPharma Enters Oversold Territory

by Zacks Equity Research

PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

by Zacks Equity Research

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal

by Zacks Equity Research

Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.

AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

by Zacks Equity Research

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

Axsome (AXSM) Completes Patient Randomization in TRD Study

by Zacks Equity Research

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

by Zacks Equity Research

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

by Zacks Equity Research

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

Why Is PDL BioPharma (PDLI) Up 5.3% Since Last Earnings Report?

by Zacks Equity Research

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales

by Zacks Equity Research

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.

Why Is PDL BioPharma (PDLI) Down 20.1% Since Last Earnings Report?

by Zacks Equity Research

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

PDL BioPharma (PDLI) Down 9.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts

by Zacks Equity Research

PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

by Zacks Equity Research

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

by Zacks Equity Research

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

by Zacks Equity Research

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

by Zacks Equity Research

Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

by Zacks Equity Research

AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.